Opel Vauxhall Finance Goes Live in Spain With Nucleus Software’s Flagship Lending Product, FinnOne
Opel Vauxhall Finance announces the going live in Spain of Nucleus Software’s flagship lending product, FinnOne. Nucleus Software is the leading provider of lending and transaction banking products and solutions to the global financial industry. Spain becomes the ninth European country for Opel Vauxhall Finance (OVF) to go live with FinnOne.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005757/en/
OVF is the automotive finance captive organization of Opel and Vauxhall, supported by Stellantis and BNP Paribas. OVF trades under strong local brands such as Opel Bank, Opel Financial Services and Vauxhall Finance. OVF has multiple operational branches across Europe, each operating under local bank licence or Financial Institution.
While FinnOne has been supporting businesses for Opel Vauxhall Finance in Europe since 2006, Spain is the latest country that will run OVF business using FinnOne. The OVF FinnOne partnership began in Italy and then moved on to Belgium, Netherlands, UK, France, Germany, Austria and Switzerland. The OVF portfolio includes a wide range of auto financing products, including consumer loans, leasing, insurance and service contracts.
Opel Vauxhall Finance wanted to utilize its core applications to achieve economies of scale. Nucleus Software FinnOne SRS (Strategic Retail Solution) is helping OVF in leveraging existing functionalities and aligning Spanish business processes to the OVF strategic applications rather than customizing and increasing scope & cost.
“With FinnOne going live in Spain, Opel Vauxhall Finance will be able to improve operational efficiency and align with the corporate strategic technology framework. With enhanced digitization, we will also be able to strengthen the collaboration framework with Opel/Vauxhall to increase the volume of financed/leased vehicles while at the same time raising retail margins across Europe,” says Alexandre Sorel, CEO of Opel Vauxhall Finance.
“We are proud to continue to bring value to our long-term partnership with Opel Vauxhall Finance (OVF). Spain is the ninth European country where FinnOne is supporting OVF in running their complex business. Having a common solution running across nine countries provides a competitive edge to OVF in terms of operational efficiency, uniform rollouts and standardization. We were able to go live despite the pandemic by meeting business commitments thanks to the coming together of OVF and Nucleus teams using our deep expertise in off-shore implementation methodology,” says Parag Bhise, CEO, Nucleus Software.
About Opel Vauxhall Finance:
OVF (Opel Vauxhall Finance) is the automotive finance captive organization of Opel and Vauxhall, supported by Stellantis and BNP Paribas, taken over from GM Financial in 2017. OVF trades under strong local brands such as Opel Bank, Opel Financial Services and Vauxhall Finance. OVF has multiple operational branches across Europe, each operating under local bank licence or Financial Institution. For IT Operations, everything is controlled from UK under the name Opel Vauxhall Finance.
Its portfolio includes a wide range of auto financing products, including consumer loans, leasing, insurance and service contracts as well as dealer financing. In Germany, OVF also offer money market accounts and fixed-term deposits directly to end-consumers, complementing our traditional automotive finance business.
OVF's primary goal is to meet the mobility needs of customers across Europe, while sustaining and developing the Opel and Vauxhall brands through competitive and attractive automotive finance solutions. Financing Opel and Vauxhall Brands dates back to 1920 when it opened its first office in London, helping people in the UK to finance their vehicles. In 1929 Opel Finanzierungsgesellschaft mbH was founded in Russelsheim, Germany, as the strategic finance partner for Opel.
About Nucleus Software:
Nucleus Software Exports Ltd. is a publicly traded (BSE: 531209, NSE: NUCLEUS) software product company that provides lending and transaction banking products to global financial leaders.
Nucleus Software powers the operations of more than 200 Financial Institutions in over 50 countries, supporting retail lending, corporate banking, cash management, mobile and internet banking, automotive finance and other business areas. Its products facilitate more than 26 million transactions each day, managing over US $200 billion of loans and enabling more than 200,000 users logging in daily.
For more information, please visit: www.nucleussoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005757/en/
Contact information
Dr. Ritika Dusad
ritika.dusad@nucleussoftware.com
Nucleus Software
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom